


FIGURE S1. Study design



*Olanzapine dosing was flexible (5–20 mg/day); †randomization was stratified by weight change during the 1-week open-label olanzapine lead-in period.

TABLE S1. Patient baseline demographics and characteristics*

Category	Olanzapine + placebo (N = 75)		Olanzapine + samidorphan 5 mg (N = 80)		Olanzapine + samidorphan 10 mg (N = 86)		Olanzapine + samidorphan 20 mg (N = 68)		All olanzapine + samidorphan (N = 234)		All patients (N = 309)	
	Years	SD	Years	SD	Years	SD	Years	SD	Years	SD	Years	SD
Age	40.3	8.1	37.9	8.6	38.1	8.0	39.3	8.4	38.4	8.3	38.8	8.3
Male	n	%	n	%	n	%	n	%	n	%	n	%
	53	70.7	60	75.0	65	75.6	50	73.5	175	74.8	228	73.8
Primary race												
Black/African-American	44	58.7	53	66.3	50	58.1	42	61.8	145	62.0	189	61.2
White	28	37.3	26	32.5	35	40.7	23	33.8	84	35.9	112	36.2
Other	3	4.0	0		1	1.2	3	4.4	4	1.7	7	2.3
Ethnicity												
Hispanic or Latino	4	5.3	5	6.3	5	5.8	3	4.4	13	5.6	17	5.5
Not Hispanic or Latino	71	94.7	75	93.8	81	94.2	65	95.6	221	94.4	292	94.5
Region												
US	60	80.0	68	85.0	70	81.4	60	88.2	19	84.6	258	83.5
Non-US	15	20.0	12	15.0	16	18.6	8	11.8	36	15.4	51	16.5
Weight	kg	SD	kg	SD	kg	SD	kg	SD	kg	SD	kg	SD
	75.6	12.3	77.5	13.1	76.7	13.7	75.4	12.8	76.6	13.2	76.4	13.0
BMI	kg/m ²	SD	kg/m ²	SD	kg/m ²	SD	kg/m ²	SD	kg/m ²	SD	kg/m ²	SD
	25.1	3.4	25.7	3.2	25.0	3.2	24.8	3.4	25.2	3.3	25.	3.3
PANSS total score	Score	SD	Score	SD	Score	SD	Score	SD	Score	SD	Score	SD
	62.7	10.1	61.7	10.0	62.6	9.8	64.5	9.5	62.8	9.8	62.8	9.9
CGI-S	Score	SD	Score	SD	Score	SD	Score	SD	Score	SD	Score	SD
	2.9	0.31	2.8	0.41	2.8	0.39	2.9	0.29	2.9	0.37	2.9	0.4
Concomitant medication												
	n	%	n	%	n	%	n	%	n	%	n	%
Lorazepam	4	5.3	3	3.8	6	7.0	8	11.8	17	7.3	38	12.3
Benzatropine mesilate	3	4.0	6	7.5	5	5.8	7	10.3	18	7.7	39	12.6
Contraceptives [†]	23	30.7	17	21.3	20	23.3	17	25.0	54	23.1	131	42.4
Trazodone	4	5.3	2	2.5	10	11.6	9	13.2	21	9.0	46	14.9
Risperidone	5	6.7	8	10.0	8	9.3	3	4.4	19	8.1	43	13.9
Ibuprofen	9	12.0	3	3.8	4	4.7	9	13.2	16	6.8	41	13.3

*Percentages are based on the number of patients in the safety population; [†]Contraceptives include intrauterine devices and intravaginal contraceptives. All values are mean ± SD. BMI, body mass index; CGI-S, Clinical Global Impressions-Severity; PANSS, Positive and Negative Syndrome Scale.